Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily

Zittermann, Armin; Ernst, Jana B.; Prokop, Sylvana; Fuchs, U; Dreier, Jens; Kühn, Joachim; Knabbe, Cornelius; Birschmann, Ingvíld; Schulz, Uwe; Berthold, Heiner K.; Pilz, Stefan; Gouni‐Berthold, Ioanna; Gummert, Jan; Dittrich, Marcus; Börgermann, Jochen

doi:10.1093/eurheartj/ehx235

Cited by 152 publications

(130 citation statements)

References 25 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…EVITA was neutral for mortality and heart failure hospitalisation [62]. EVITA recruited only 400 of an intended 950 subjects (which would have given 80% power to detect a 36% reduction in total mortality) and had a drop-out rate of 42% at 3 years.…”

Section: Vitamin D As An Interventionmentioning

confidence: 99%

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Vitamin D As An Interventionmentioning

confidence: 99%

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, new randomized controlled trials with moderate or high doses of vitD rendered dissimilar results. For instance, vitD supplements failed to demonstrate systemic antihypertensive effects or to reduce cardiovascular events [13][14][15], but succeeded in reducing asthma [16] and chronic obstructive pulmonary disease (COPD) [17] exacerbations in patients with baseline 25(OH)vitD levels lower than 25 nmol/L (10 ng/mL) About 85% of total 25(OH)vitD is bound to vitD-binding protein (DBP), about 15% is bound to albumin, and only less than 1% is free [18]. Albumin-bound 25(OH)vitD dissociates rapidly and is also biologically available in tissues, and DBP acts as a reservoir for vitD.…”

Section: Introductionmentioning

confidence: 99%

Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension

Callejo

Mondéjar-Parreño

Esquivel-Ruiz

et al. 2020

JCM

View full text Add to dashboard Cite

Introduction: Epidemiological studies suggest a relationship between vitamin D deficiency and cardiovascular and respiratory diseases. However, whether total, bioavailable, and/or free vitamin D levels have a prognostic role in pulmonary arterial hypertension (PAH) is unknown. We aimed to determine total, bioavailable, and free 25-hydroxy-vitamin D (25(OH)vitD) plasma levels and their prognostic value in PAH patients. Methods: In total, 67 samples of plasma from Spanish patients with idiopathic, heritable, or drug-induced PAH were obtained from the Spanish PH Biobank and compared to a cohort of 100 healthy subjects. Clinical parameters were obtained from the Spanish Registry of PAH (REHAP). Results: Seventy percent of PAH patients had severe vitamin D deficiency (total 25(OH)vitD < 10 ng/mL) and secondary hyperparathyroidism. PAH patients with total 25(OH)vitD plasma above the median of this cohort (7.17 ng/mL) had better functional class and higher 6-min walking distance and TAPSE (tricuspid annular plane systolic excursion). The main outcome measure of survival was significantly increased in these patients (age-adjusted hazard ratio: 5.40 (95% confidence interval: 2.88 to 10.12)). Vitamin D-binding protein (DBP) and albumin plasma levels were downregulated in PAH. Bioavailable 25(OH)vitD was decreased in PAH patients compared to the control cohort. Lower levels of bioavailable 25(OH)vitD (<0.91 ng/mL) were associated with more advanced functional class, lower exercise capacity, and higher risk of mortality. Free 25(OH)vitD did not change in PAH; however, lower free 25(OH)vitD (<1.53 pg/mL) values were also associated with high risk of mortality. Conclusions: Vitamin D deficiency is highly prevalent in PAH, and low levels of total 25(OH)vitD were associated with poor prognosis.

show abstract

“…shown to reduce inflammation (Schleithoff et al, 2006) and mortality (Gotsman et al, 2012), increase ejection fraction and decrease systolic blood pressure (Dalbeni et al, 2014). A research group, however, did not observe the effect of supplementation of vitamin D in the outcome of patients with advanced heart failure (Zittermann et al, 2017). This group performed the EVITA trial, which aimed to evaluate the effects of vitamin D on different parameters of heart failure in humans.…”

Section: In Humans Vitamin D Supplementation In Chf Patients Has Beenmentioning

confidence: 99%

“…Meta-analysis studies have shown that serum concentrations of 25(OH)D may be independent predictors of survival in people with a wide variety of diseases (Schöttker et al, 2014), and the prevalence of lower vitamin D concentrations in critically ill people is about 82% (Melamed et al, 2008). However, the mortality of human patients with advanced heart failure supplemented with vitamin D for 3 years did not differ from that of patients that received placebo for the same period of time (Zittermann et al, 2017).…”

Section: Vitamin D As a Predictor Of Mortalitymentioning

confidence: 99%

Vitamin D metabolism in dogs and cats and its relation to diseases not associated with bone metabolism

Zafalon

Risolia

Pedrinelli

et al. 2019

Animal Physiology Nutrition

View full text Add to dashboard Cite

Due to the presence of receptors in the cells of numerous body tissues, vitamin D is associated with several physiological functions that go beyond calcium and phosphorus homoeostasis and control of bone metabolism in the body. In humans, several studies have associated lower vitamin D concentrations with numerous diseases, such as cancer, heart disease, autoimmune diseases and infectious diseases, and also with an increase in the total mortality rate of the population. Recently, this nutrient started to gain importance in veterinary medicine, and several articles have shown a correlation between low vitamin D status and diseases unrelated to bone metabolism. The present review aims to highlight the recent publications that investigated this relationship, bringing the evidence that exists so far in dogs and cats. K E Y W O R D S1,25(OH)2D, 25(OH)D, calcidiol, calcitriol, cholecalciferol, hypovitaminosis D

show abstract

Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily

Abstract: clinicaltrials.gov Idenitfier: NCT01326650.

Cited by 152 publications

References 25 publications

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure

Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension

Vitamin D metabolism in dogs and cats and its relation to diseases not associated with bone metabolism

Contact Info

Product

Resources

About